Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Innate Pharma patents

Recent patent applications related to Innate Pharma. Innate Pharma is listed as an Agent/Assignee. Note: Innate Pharma may have other listings under different names/spellings. We're not affiliated with Innate Pharma, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Innate Pharma-related inventors

Combination of anti-kir and anti-ctla-4 antibodies to treat cancer

Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-kir antibody in combination with an anti-ctla-4 antibody.. . ... Innate Pharma

Cd73 blockade

This invention relates to antibodies that bind an epitope present on cd73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the cd73 enzyme. Such agents can be used for the treatment of diseases such as cancers.. ... Innate Pharma

Monomeric fc domains

Monomeric fc-domains are provided, as well as multimeric and single chain proteins comprising the monomeric fc-domains. The proteins have utility in the treatment of disease. ... Innate Pharma

Cross reactive siglec antibodies

This invention relates to agents that bind multiple siglecs, including antibodies that neutralize the inhibitory activity of multiple siglec-7 and siglec-9 in lymphocytes. Such agents can be used for the treatment of cancers or infectious disease.. ... Innate Pharma

Neutralization of inhibitory pathways in lymphocytes

The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human nkg2a in combination with compounds that bind and inhibit human pd-1. The invention also relates to assays to identify nkg2a+pd1+ tumor infiltrating nk and/or cd8 t cells.. ... Innate Pharma

Anti-mica antibodies

The present invention provides antigen-binding proteins capable of binding to human mica polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by mica-expressing cells, particularly cancer.. ... Innate Pharma

Multispecific antigen binding proteins

Multimeric multispecific proteins formed from dimerization between ch1 and ck domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.. ... Innate Pharma

Multispecific nkp46 binding proteins

Multispecific proteins that bind and specifically redirect nk cells to lyse a target cell of interest are provided without non-specific activation of nk cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.. ... Innate Pharma

Humanized antibodies with increased stability

The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to kir3dl2 polypeptides. ... Innate Pharma

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Innate Pharma in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Innate Pharma with additional patents listed. Browse our Agent directory for other possible listings. Page by